Always verify pricing and state availability on the provider's website before signing up.How our reviews work →
Care Bare Rx vs Zealthy
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
7.4
Care Bare Rx
Best for LGBTQ+-inclusive compounded GLP-1 telehealth★★★★☆3.7
Starting at $199/mo
CompoundedBrandSemaglutideTirzepatide
Visit Care Bare Rx →4.8
Zealthy
Best for not currently recommended — listed for transparency and reader awareness only★★☆☆☆2.4
Starting at $286/mo
CompoundedSemaglutideTirzepatide
Visit Zealthy →Side-by-Side Comparison
| Feature | Care Bare Rx | Zealthy |
|---|---|---|
| Overall Score | ✓7.4/10 | 4.8/10 |
| Starting Price | ✓$199/mo | $286/mo |
| Editorial Rating | ✓3.7 ★ /5 | 2.4 ★ /5 |
| Features | ✓6 features | 3 features |
| States Available | 0 | ✓34 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | ✓ Yes | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | ✓None | 2 warnings |
Pros & Cons
Care Bare Rx
Pros
- ✓Explicit LGBTQ+-inclusive, 'self-care with pride' positioning — one of the few GLP-1 telehealth brands with this framing
- ✓All 50 states + Puerto Rico coverage
- ✓Offers both compounded options ($199/mo) and brand-name Ozempic ($705/mo) — unusual flexibility in the compounded-first telehealth segment
- ✓Same named medical team as Breeze Meds and Synergy Rx: Dr. Ana Lisa Carr MD (NPI 1689841744) and Dr. Kelly Tenbrink MD (NPI 1346482684)
- ✓Four named 503A pharmacy partners (Belmar, Strive, Epiq Scripts, Casa Pharma Rx)
- ✓No FDA warnings or litigation on record
Cons
- ✗Runs on the same Lion MD clinician network and the same 4 compounding pharmacies as Breeze Meds and Synergy Rx — the three brands are white-labeled storefronts on top of one underlying operation, not three independent providers
- ✗Compounded medications are not FDA-approved
- ✗Despite the LGBTQ+ positioning, no formal gender-affirming care pathway or HRT integration is mentioned — the inclusive framing is editorial rather than a clinical specialty
- ✗Limited accreditation transparency beyond LegitScript claim — no PCAB/ACHC seal on site
- ✗Pharmacy partners are named but per-batch third-party testing and accreditation details are not independently disclosed
Zealthy
Pros
- ✓34 states served — meaningful nationwide footprint
- ✓Asynchronous model removes friction for patients comfortable without a synchronous video visit
- ✓Independent licensed prescribers retain full clinical authority
Cons
- ✗TWO FDA warning letters for false/misleading marketing of compounded GLP-1s (Feb 2026 letter 717987 verified at fda.gov; September 2025 letter from secondary sources)
- ✗Active Novo Nordisk false-advertising lawsuit: Novo Nordisk A/S et al v. Zealthy Inc., case 1:25-cv-06391 (S.D.N.Y., filed 2025-08-04), alleging trademark infringement and marketing of compounded products as 'FDA-approved alternatives'
- ✗Active DOJ/FTC enforcement: United States v. Cerebral, Inc. et al, case 1:24-cv-21376 (S.D. Fla., amended complaint adding Zealthy Inc., Gronk Inc., founder Kyle Robertson, and others), alleging ROSCA violations (failure to disclose subscription terms, no informed consent for billing, locked cancellation), and unauthorized health-data sharing for targeted advertising
- ✗Founder pattern of conduct: Kyle Robertson previously founded Cerebral, which settled with the FTC in June 2024 ($5M consumer redress + $10M civil penalty suspended to $2M) for similar deceptive practices. Robertson then founded Zealthy and is alleged to have continued the same conduct
- ✗Company recently renamed FitRX/Zealthy to Gronk Inc. — rebrand pattern is itself a concerning signal in the context of active enforcement
- ✗Continued marketing of compounded semaglutide after FDA removed it from the shortage list on 2025-02-21 (post-shortage compounding without legal authorization)
- ✗Adds a $135/month membership fee on top of medication cost — total cash price is $286-$351/month
- ✗Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro option
Our Verdict
Winner: Care Bare RxScore: 7.4/10
Care Bare Rx edges out Zealthy with a higher overall score of 7.4/10 and is particularly strong for LGBTQ+-inclusive compounded GLP-1 telehealth. Zealthy remains a solid alternative, especially if you're looking for not currently recommended — listed for transparency and reader awareness only.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.